223673-34-5

Basic information

• Product Name: (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol
• Synonyms: (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol;BenzeneMethanol, a-[[[2-(4-nitrophenyl)ethyl]aMino]Methyl]-, (aR)-;BenzeneMethanol, -[[[2-(4-nitrophenyl)ethyl]aMino]Methyl]-, (R)-;(R)--[[[2-(4-nitrophenyl)ethyl]aMino]Methyl]-BenzeneMethanol;Mirabegron INT 2;(alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethan;(R)-2-(4-nitrophenethylamino)-1-phenylethanol;(R)-2-((4-nitrophenethyl)amino)-1-phenylethan-1-ol
• CAS NO: 223673-34-5
• Molecular Formula: C16H18N2O3
• Molecular Weight: 286.32572
• Mol File: 223673-34-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 472.5±24.0 °C(Predicted)
• Appearance: /
• Density: 1.219
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 13.95±0.20(Predicted)
• CAS DataBase Reference: (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol(223673-34-5)
• EPA Substance Registry System: (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol(223673-34-5)

Safety Data

• Hazardous Substances Data: 223673-34-5(Hazardous Substances Data)

Usage

General Description

The chemical compound "(alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol" is an organic compound that is a derivative of benzenemethanol. It has a nitrophenyl group attached to an ethylamino group, which in turn is attached to the benzenemethanol structure. (alphaR)-alpha-[[[2-(4-Nitrophenyl)ethyl]amino]methyl]benzenemethanol is a chiral molecule with an alphaR configuration. It may have potential applications in pharmaceuticals and organic synthesis due to its complex structure and potential reactivity. However, further research and testing are necessary to fully understand its properties and potential uses.

Upstream product

• 20780-53-4 (R)-Styrene oxide 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 521284-19-5 (2R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylethanamide 
• 70-11-1 α-bromoacetophenone 
• 611-71-2 (R)-Mandelic Acid 
• 1460-05-5 p-nitrophenylacetaldehyde 
• 2549-14-6 (R)-2-Amino-1-phenylethanol 
• 555-21-5 4-Nitrophenylacetonitrile 
• 29968-78-3 2-(4-nitrophenyl)ethylamine monohydrochloride 

Downstream Products

• 521284-21-9 (R)-2-[[2′-(4-nitrophenyl)ethyl]amino]-1-phenylethanol hydrochloride 

Relevant articles and documents

Targeting a Mirabegron precursor by BH3-mediated continuous flow reduction process

A continuous-flow reduction of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide, involved in the synthetic pathway of Mirabegron, has been developed. This study demonstrated the possibility to safely handling BH3 complexes within microfluidic reactors using 2-MeTHF as greener alternative to traditional solvents, and without requiring any additive such as DMI. In addition, NMR and HPLC purity analysis revealed that the sole by-product of this process is the diamine 3, which wouldn't affect the following synthetic steps towards Mirabegron.

Nitrogen heterocyclic ring group substituted amide derivative and application thereof

The invention discloses a nitrogen heterocyclic ring group substituted amide derivative and application thereof, particularly relates to a novel nitrogen heterocyclic ring group substituted amide derivative and a drug composition comprising the compound, and further relates to methods for preparing the compound and the drug composition, and application of the compound and the drug composition to preparation of drugs for treating diseases or symptoms, particularly overactive bladder, excited and mediated by beta 3-adrenergic receptors. The compound and the drug composition can be used for activating the beta 3-adrenergic receptors.

Aryl or heteroaryl substituted pyrrolidine amide derivatives and application thereof

The invention discloses aryl or heteroaryl substituted pyrrolidine amide derivatives and an application thereof, in particular to a novel aryl or heteroaryl substituted pyrrolidine amide derivative and a pharmaceutical composition containing the same, which can be used for activating beta3-adrenergic receptor. The invention also relates to a method for preparing the compounds and pharmaceutical compositions, as well as an application thereof in preparing drugs for treating diseases or symptoms mediated by beta3-adrenergic receptor, and especially for treating the overactive bladder.